Stockscreener 앱 받기
8.65
2.15%
-0.19
시간 외 거래:
8.64
-0.010
-0.12%
전일 마감가:
$8.84
열려 있는:
$8.77
하루 거래량:
32,582
Relative Volume:
0.48
시가총액:
$736.06M
수익:
$213.45M
순이익/손실:
$-72.46M
주가수익비율:
-8.7057
EPS:
-0.9936
순현금흐름:
$-47.28M
1주 성능:
-2.26%
1개월 성능:
+9.91%
6개월 성능:
+21.23%
1년 성능:
+22.28%
1일 변동 폭
$8.64
$8.84
1주일 범위
$8.0528
$9.11
52주 변동 폭
$3.62
$12.25
발네바 Stock (VALN) Company Profile
VALN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
8.65 | 759.05M | 213.45M | -72.46M | -47.28M | -0.9936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
발네바 Stock (VALN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 재개 | H.C. Wainwright | Buy |
| 2022-08-03 | 개시 | H.C. Wainwright | Buy |
발네바 주식(VALN)의 최신 뉴스
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - ACCESS Newswire
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ - MSN
Valneva selloff on FDA suspension overdone, says H.C. Wainwright - MSN
Valneva SE ADR: Rising -26.86% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Valneva price target lowered to $14 from $18 at Jefferies - MSN
Jefferies lowers Valneva stock price target to $14 on FDA suspension - Investing.com
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine By Investing.com - Investing.com South Africa
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine - Investing.com
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. - GlobeNewswire Inc.
Valneva (NASDAQ:VALN) Shares Gap Up – Still a Buy? - Defense World
HC Wainwright Estimates Valneva’s Q3 Earnings (NASDAQ:VALN) - Defense World
Valneva (NASDAQ:VALN) Coverage Initiated by Analysts at HC Wainwright - Defense World
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 91.2% - Defense World
Valneva (NASDAQ:VALN) Trading Up 14.3% After Better-Than-Expected Earnings - Defense World
Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Valneva SE earnings beat by $0.22, revenue topped estimates - Investing.com
Valneva (NASDAQ:VALN) Trading Down 6.7% – Here’s What Happened - Defense World
Valneva (NASDAQ:VALN) Sets New 1-Year High – Still a Buy? - Defense World
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock? - Yahoo Finance
[Valneva SE] Declaration of shares and voting rights - GlobeNewswire Inc.
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - Business Wire
발네바 (VALN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):